Reinstatement to Reduce Withdrawal

What is Reinstatement?

Reinstatement is the reintroduction of a psychiatric medication following the onset of withdrawal symptoms. According to current psychopharmacological literature, reinstatement is the primary medical intervention for mitigating severe or intolerable withdrawal.¹ When a drug is discontinued, the nervous system- which has adapted to the presence of the drug- is left in an uncompensated state. Reintroducing the medication can alleviate withdrawal symptoms, sometimes relatively rapidly.²

The Window of Opportunity

Reinstatement is generally considered most likely to be successful when initiated as soon as possible after the onset of withdrawal symptoms or abrupt cessation.¹ There is sometimes discussion within withdrawal communities of a fixed “three-month window”; however, there is no established universal cut-off. The reality is that the length of the window of opportunity is unknown and varies considerably between individuals.²

What is known, is the longer a patient remains off the medication, the less predictable the response to reinstatement becomes.¹ There are currently no clear factors that reliably predict an individual's response.¹

Reinstatement also does not necessarily produce immediate relief; NICE advises that withdrawal symptoms may take several days to resolve even after the antidepressant has been restarted or the dose increased.¹

Hyperbolic Binding and Micro-Dosing 

Non-Linear Receptor Occupancy: PET imaging demonstrates that psychiatric drugs (especially SSRIs/SNRIs) exhibit a hyperbolic dose-response curve.⁴ Small doses occupy a disproportionately large percentage of neurotransmitter transporters. For example, PET data have found approximately 30% serotonin-transporter occupancy at just 1 mg of fluoxetine, illustrating how even very low doses can retain substantial pharmacological activity.⁵

Sensitivity Following Withdrawal: Following withdrawal, some patients report increased sensitivity to medication changes or difficulty tolerating reinstatement. Peer withdrawal communities consequently advocate particular caution when reinstating after a period off medication. This phenomenon is sometimes described within these communities in terms of nervous-system “sensitisation” or “kindling”. 

Determining the Reinstatement Dose

Clinical guidance and peer-support approaches differ regarding reinstatement dosage. NICE advises considering restarting the original antidepressant at the previous dose in cases of more severe withdrawal.¹ Some specialist withdrawal communities instead advocate cautious low-dose reinstatement, particularly where a person appears highly sensitised, followed by observation before making further adjustments.⁶

The target reinstatement dose depends on time elapsed, previous dosage, and nervous system sensitivity. 

For detailed peer-support information on psychiatric medication reinstatement, including timing, stabilisation and factors that may influence reinstatement dose, see the SurvivingAntidepressants Reinstatement Guide.

For additional information specifically concerning benzodiazepine reinstatement, see Notes on Reinstatement — BenzoSupport.org.

These are independent peer-support resources and should not be interpreted as individual medical advice or formal clinical guidelines.

References

1. National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NG222). NICE. https://www.nice.org.uk/guidance/NG222/chapter/recommendations

2. Horowitz, M. A., & Taylor, D. (2022). Distinguishing relapse from antidepressant withdrawal: Clinical practice and antidepressant discontinuation studies. BJPsych Advances, 28(5), 297–311.

3. SurvivingAntidepressants.org. (2012). Reinstatement: About reinstating and stabilizing to reduce withdrawal symptoms. [Peer-support guidance based on accumulated patient experience.]

4. ⁴ Sørensen, A., Ruhé, H. G., & Munkholm, K. (2022). The relationship between dose and serotonin transporter occupancy of antidepressants—A systematic review. Molecular Psychiatry, 27, 192–201. https://doi.org/10.1038/s41380-021-01285-w

5. Meyer, J. H., Wilson, A. A., Sagrati, S., et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [¹¹C]DASB positron emission tomography study. American Journal of Psychiatry, 161(5), 826–835. https://doi.org/10.1176/appi.ajp.161.5.826